Current Status of Colorectal Cancer Therapy

2007 ◽  
pp. 273-285
Author(s):  
John Strother ◽  
Kevin G. Billingsley ◽  
Arthur Y. Hung ◽  
Charles D. Blanke
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Current Status

Radioimmunoscintigraphy for colorectal cancer: Current status and future prospects

2002 ◽  
Vol 13 (2) ◽  
pp. 119-126
Author(s):  
Frederick L. Moffat ◽  
Aldo N. Serafini
Keyword(s):  
Colorectal Cancer ◽  
Current Status ◽  
Future Prospects

Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications

2015 ◽  
Vol 15 (2) ◽  
pp. 116-135 ◽  
Author(s):  
Jawed Siddiqui ◽  
Aru Singh ◽  
Megha Chagtoo ◽  
Nidhi Singh ◽  
Madan Godbole ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Current Status ◽  
Breast Cancer Therapy

scholarly journals The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy

2021 ◽  
Vol 137 ◽  
pp. 111364
Author(s):  
Zahra Asadzadeh ◽  
Behzad Mansoori ◽  
Ali Mohammadi ◽  
Tohid Kazemi ◽  
Ahad Mokhtarzadeh ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Combination Effect ◽  
Oxaliplatin Treatment

scholarly journals Targeting the Metabolic Adaptation of Metastatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1641
Author(s):  
Josep Tarragó-Celada ◽  
Marta Cascante
Keyword(s):  
Colorectal Cancer ◽  
Cancer Metastasis ◽  
Metastatic Cancer ◽  
Breast Cancer Metastasis ◽  
Metabolic Inhibitors ◽  
Current Status ◽  
Metabolic Adaptation ◽  
Metastatic Cells ◽  
Colorectal Cancer Metastasis ◽  
Metastatic Process

Metabolic adaptation is emerging as an important hallmark of cancer and metastasis. In the last decade, increasing evidence has shown the importance of metabolic alterations underlying the metastatic process, especially in breast cancer metastasis but also in colorectal cancer metastasis. Being the main cause of cancer-related deaths, it is of great importance to developing new therapeutic strategies that specifically target metastatic cells. In this regard, targeting metabolic pathways of metastatic cells is one of the more promising windows for new therapies of metastatic colorectal cancer, where still there are no approved inhibitors against metabolic targets. In this study, we review the recent advances in the field of metabolic adaptation of cancer metastasis, focusing our attention on colorectal cancer. In addition, we also review the current status of metabolic inhibitors for cancer treatment.

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Small Proportion ◽  
Biomarker Testing ◽  
Over Time

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.

scholarly journals Clostridial Spores for Cancer Therapy: Targeting Solid Tumour Microenvironment

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Brittany Umer ◽  
David Good ◽  
Jozef Anné ◽  
Wei Duan ◽  
Ming Q. Wei
Keyword(s):  
Cancer Therapy ◽  
Solid Tumour ◽  
Early Stage ◽  
Treatment Options ◽  
Anaerobic Bacteria ◽  
Past Research ◽  
Tumour Microenvironment ◽  
The Body ◽  
Solid Tumours ◽  
Current Status

Solid tumour accounts for 90% of all cancers. The current treatment approach for most solid tumours is surgery, however it is limited to early stage tumours. Other treatment options such as chemotherapy and radiotherapy are non-selective, thus causing damage to both healthy and cancerous tissue. Past research has focused on understanding tumour cells themselves, and conventional wisdom has aimed at targeting these cells directly. Recent research has shifted towards understanding the tumour microenvironment and it’s differences from that of healthy cells/tissues in the body and then to exploit these differences for treatmeat of the tumour. One such approach is utilizing anaerobic bacteria. Several strains of bacteria have been shown to selectively colonize in solid tumours, making them valuable tools for selective tumour targeting and destruction. Amongst them, the anaerobicClostridiumhas shown great potential in penetration and colonization of the hypoxic and necrotic areas of the tumour microenvironment, causing significant oncolysis as well as enabling the delivery of therapeutics directly to the tumourin situ. Various strategies utilizingClostridiumare currently being investigated, and represent a novel area of emerging cancer therapy. This review provides an update review of tumour microenvironment as well as summary of the progresses and current status of Clostridial spore-based cancer therapies.

Sign in / Sign up

Export Citation Format

Share Document